---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-24-000002"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:05:34.299975+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AbbVie updates Q4 and FY 2023 adjusted EPS guidance for $282M IPR&D expense

## Summary
- Q4 2023 acquired IPR&D and milestones expense of $282M pre-tax reduces GAAP and adjusted EPS by $0.15.
- Updated Q4 2023 adjusted diluted EPS guidance range: $2.72 - $2.76 (prior $2.87 - $2.91).
- Full-year 2023 adjusted diluted EPS guidance now $11.04 - $11.08 (prior $11.19 - $11.23).
- Full-year 2023 acquired IPR&D and milestones expense totals $778M.
- AbbVie notes these expenses are inherently unforecastable; final Q4 results may differ.

## SEC filing metadata
- accession: 0001551152-24-000002
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000002/0001551152-24-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000002/abbv-20240105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-24-000002
- JSON: https://secwatch.observer/filing/0001551152-24-000002.json
- Plain text: https://secwatch.observer/filing/0001551152-24-000002.txt

## Key facts
- Earnings Releases
  AbbVie Inc. reported full-year ended December 31, 2023 results: EPS $11.04 - $11.08. Guidance reaffirmed.
  - Period: full-year ended December 31, 2023
  - EPS: $11.04 - $11.08
  - Guidance: reaffirmed
  - Result: guidance update
  source text: AbbVie’s full-year 2023 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2023 acquired IPR&D and milestones expense, is $11.04 - $11.08.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000002/0001551152-24-000002-index.htm
- Earnings Releases
  AbbVie Inc. reported quarter ended December 31, 2023 results: EPS $2.72 - $2.76. Guidance reaffirmed.
  - Period: quarter ended December 31, 2023
  - EPS: $2.72 - $2.76
  - Guidance: reaffirmed
  - Result: guidance update
  source text: AbbVie’s fourth quarter 2023 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2023 acquired IPR&D and milestones expense, is $2.72 - $2.76.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000002/0001551152-24-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.